Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Completed · Phase 2
Conditions studied: Recurrent Melanoma, Stage III Skin Melanoma, Stage IV Skin Melanoma
In brief
This phase II trial is studying how well giving bevacizumab together with sorafenib works in treating patients with unresectable stage III or stage IV malignant melanoma. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab and sorafenib may also stop the growth of melanoma by blocking blood flow to the tumor. Giving bevacizumab together with sorafenib may kill more tumor cells.
Key facts
- Study ID
- NCT00387751
- Run by
- National Cancer Institute (NCI)
- People needed
- 14
- Starts
- 2006-08-01
- Expected to finish
- 2010-01-01
- Last updated by the study team
- 2017-11-22
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Cancer Therapy and Research Center at The UT Health Science Center at San Antonio — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.